The Latest in Myelofibrosis - 100038


The Latest in Myelofibrosis

patientpower has 2417 videos Subscribe Here

Description: As genetic mutations for various cancer types are discovered, researchers have gone to work developing new medicines that inhibit those mutations. Such is the case with the JAK2 mutation now tied to myelofibrosis and scarring in the bone marrow. The first JAK2 inhibitor, Jakafi (ruxolitinib), is now approved in the U.S. and Europe. Dr. Tiziano Barbui, a myelofibrosis expert from Italy, explains how the new medicine can help.
Shared By : patientpower
Posted on : 09/26/12
Added : 5 years ago
Category : General